PMS-PIROXICAM SUPPOSITORIES -20MG SUPPOSITORY
País: Canadà
Idioma: anglès
Font: Health Canada
Fitxa tècnica
(SPC)
01-03-2010
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
PIROXICAM
Disponible des:
PHARMASCIENCE INC
Codi ATC:
M01AC01
Designació comuna internacional (DCI):
PIROXICAM
Dosis:
20MG
formulario farmacéutico:
SUPPOSITORY
Composición:
PIROXICAM 20MG
Vía de administración:
RECTAL
Unidades en paquete:
30 SUPPOSITORIES
tipo de receta:
Prescription
Área terapéutica:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Resumen del producto:
Active ingredient group (AIG) number: 0114612001; AHFS:
Estat d'Autorització:
CANCELLED POST MARKET
Data d'autorització:
2016-10-28
Fitxa tècnica
PRODUCT MONOGRAPH
Pr
pms-PIROXICAM
Piroxicam, USP
10 mg and 20 mg Capsules
10 mg and 20 mg Suppositories
Nonsteroidal Anti-Inflammatory Drug (NSAID)
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Avenue
February 17, 2010
Montreal, Quebec
H4P 2T4
CONTROL # 131400
_ _
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS..................................................................................................14
DRUG INTERACTIONS
.................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................22
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL
PHARMACOLOGY.............................................................23
STORAGE AND
STABILITY..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................24
PART II: SCIENTIFIC INFORMATION
................................................................................26
PHARMACEUTICAL
INFORMATION..........................................................................26
CLINICAL TRIALS
..........................................................................................................27
DETAILED PHARMACOLOGY
.....................................................................................27
Llegiu el document complet
